These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35121900)

  • 1. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
    Fendler A; Au L; Shepherd STC; Byrne F; Cerrone M; Boos LA; Rzeniewicz K; Gordon W; Shum B; Gerard CL; Ward B; Xie W; Schmitt AM; Joharatnam-Hogan N; Cornish GH; Pule M; Mekkaoui L; Ng KW; Carlyle E; Edmonds K; Rosario LD; Sarker S; Lingard K; Mangwende M; Holt L; Ahmod H; Stone R; Gomes C; Flynn HR; Agua-Doce A; Hobson P; Caidan S; Howell M; Wu M; Goldstone R; Crawford M; Cubitt L; Patel H; Gavrielides M; Nye E; Snijders AP; MacRae JI; Nicod J; Gronthoud F; Shea RL; Messiou C; Cunningham D; Chau I; Starling N; Turner N; Welsh L; van As N; Jones RL; Droney J; Banerjee S; Tatham KC; Jhanji S; O'Brien M; Curtis O; Harrington K; Bhide S; Bazin J; Robinson A; Stephenson C; Slattery T; Khan Y; Tippu Z; Leslie I; Gennatas S; Okines A; Reid A; Young K; Furness AJS; Pickering L; Gandhi S; Gamblin S; Swanton C; ; Nicholson E; Kumar S; Yousaf N; Wilkinson KA; Swerdlow A; Harvey R; Kassiotis G; Larkin J; Wilkinson RJ; Turajlic S;
    Nat Cancer; 2021 Dec; 2(12):1321-1337. PubMed ID: 35121900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
    Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Byrne F; Cerrone M; Schmitt AM; Joharatnam-Hogan N; Shum B; Tippu Z; Rzeniewicz K; Boos LA; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Sarker S; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Bazin J; Gordon W; Barber T; Emslie-Henry A; Xie W; Gerard CL; Deng D; Wall EC; Agua-Doce A; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Dowdie L; Ash N; Gronthoud F; Shea RL; Gardner G; Murray D; Kinnaird F; Cui W; Pascual J; Rodney S; Mencel J; Curtis O; Stephenson C; Robinson A; Oza B; Farag S; Leslie I; Rogiers A; Iyengar S; Ethell M; Messiou C; Cunningham D; Chau I; Starling N; Turner N; Welsh L; van As N; Jones RL; Droney J; Banerjee S; Tatham KC; O'Brien M; Harrington K; Bhide S; Okines A; Reid A; Young K; Furness AJS; Pickering L; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Kumar S; Yousaf N; Jhanji S; Nicholson E; Howell M; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
    Nat Cancer; 2021 Dec; 2(12):1305-1320. PubMed ID: 35121899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
    Fendler A; Au L; Shepherd STC; Byrne F; Cerrone M; Boos LA; Rzeniewicz K; Gordon W; Shum B; Gerard CL; Ward B; Xie W; Schmitt AM; Joharatnam-Hogan N; Cornish GH; Pule M; Mekkaoui L; Ng KW; Carlyle E; Edmonds K; Del Rosario L; Sarker S; Lingard K; Mangwende M; Holt L; Ahmod H; Stone R; Gomes C; Flynn HR; Agua-Doce A; Hobson P; Caidan S; Howell M; Wu M; Goldstone R; Crawford M; Cubitt L; Patel H; Gavrielides M; Nye E; Snijders AP; MacRae JI; Nicod J; Gronthoud F; Shea RL; Messiou C; Cunningham D; Chau I; Starling N; Turner N; Welsh L; van As N; Jones RL; Droney J; Banerjee S; Tatham KC; Jhanji S; O'Brien M; Curtis O; Harrington K; Bhide S; Bazin J; Robinson A; Stephenson C; Slattery T; Khan Y; Tippu Z; Leslie I; Gennatas S; Okines A; Reid A; Young K; Furness AJS; Pickering L; Gandhi S; Gamblin S; Swanton C; Nicholson E; Kumar S; Yousaf N; Wilkinson KA; Swerdlow A; Harvey R; Kassiotis G; Larkin J; Wilkinson RJ; Turajlic S
    Res Sq; 2021 Sep; ():. PubMed ID: 34580668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection.
    Siracusano G; Brombin C; Pastori C; Cugnata F; Noviello M; Tassi E; Princi D; Cantoni D; Malnati MS; Maugeri N; Bozzi C; Saretto G; Clementi N; Mancini N; Uberti-Foppa C; Temperton N; Bonini C; Di Serio C; Lopalco L
    Front Immunol; 2021; 12():772239. PubMed ID: 34804064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
    Collier AY; McMahan K; Yu J; Tostanoski LH; Aguayo R; Ansel J; Chandrashekar A; Patel S; Apraku Bondzie E; Sellers D; Barrett J; Sanborn O; Wan H; Chang A; Anioke T; Nkolola J; Bradshaw C; Jacob-Dolan C; Feldman J; Gebre M; Borducchi EN; Liu J; Schmidt AG; Suscovich T; Linde C; Alter G; Hacker MR; Barouch DH
    JAMA; 2021 Jun; 325(23):2370-2380. PubMed ID: 33983379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination.
    Sariol CAA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina-Rodríguez A; Cruz L; Stone ETT; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AKK; Brien JDD; Espino AMM
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrete SARS-CoV-2 antibody titers track with functional humoral stability.
    Bartsch YC; Fischinger S; Siddiqui SM; Chen Z; Yu J; Gebre M; Atyeo C; Gorman MJ; Zhu AL; Kang J; Burke JS; Slein M; Gluck MJ; Beger S; Hu Y; Rhee J; Petersen E; Mormann B; Aubin MS; Hasdianda MA; Jambaulikar G; Boyer EW; Sabeti PC; Barouch DH; Julg BD; Musk ER; Menon AS; Lauffenburger DA; Nilles EJ; Alter G
    Nat Commun; 2021 Feb; 12(1):1018. PubMed ID: 33589636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.
    Markmann AJ; Giallourou N; Bhowmik DR; Hou YJ; Lerner A; Martinez DR; Premkumar L; Root H; van Duin D; Napravnik S; Graham SD; Guerra Q; Raut R; Petropoulos CJ; Wrin T; Cornaby C; Schmitz J; Kuruc J; Weiss S; Park Y; Baric R; de Silva AM; Margolis DM; Bartelt LA
    mSphere; 2021 Aug; 6(4):e0027521. PubMed ID: 34431693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection.
    Yao L; Wang GL; Shen Y; Wang ZY; Zhan BD; Duan LJ; Lu B; Shi C; Gao YM; Peng HH; Wang GQ; Wang DM; Jiang MD; Cao GP; Ma MJ
    J Infect Dis; 2021 Aug; 224(4):586-594. PubMed ID: 33978754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination.
    Paniskaki K; Anft M; Meister TL; Marheinecke C; Pfaender S; Skrzypczyk S; Seibert FS; Thieme CJ; Konik MJ; Dolff S; Anastasiou O; Holzer B; Dittmer U; Queren C; Fricke L; Rohn H; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
    Front Immunol; 2022; 13():816220. PubMed ID: 35145522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
    Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
    J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients.
    Mohn KG; Bredholt G; Zhou F; Madsen A; Onyango TB; Fjelltveit EB; Jalloh SL; Brokstad KA; Cantoni D; Mayora-Neto M; Temperton N; Langeland N; Cox RJ;
    PLoS One; 2022; 17(2):e0261979. PubMed ID: 35192617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection.
    Ansari A; Arya R; Sachan S; Jha SN; Kalia A; Lall A; Sette A; Grifoni A; Weiskopf D; Coshic P; Sharma A; Gupta N
    Front Immunol; 2021; 12():636768. PubMed ID: 33777028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Crawford KHD; Dingens AS; Eguia R; Wolf CR; Wilcox N; Logue JK; Shuey K; Casto AM; Fiala B; Wrenn S; Pettie D; King NP; Greninger AL; Chu HY; Bloom JD
    J Infect Dis; 2021 Feb; 223(2):197-205. PubMed ID: 33535236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics and Durability of Antibody and T-Cell Responses to SARS-CoV-2 in Children.
    Files MA; Gentles L; Kehoe L; Adler A; Lacombe K; Dickerson JA; Greninger A; Waghmare A; Fairlie T; Pringle K; Midgley CM; Hagen MB; Englund JA; Seshadri C
    J Infect Dis; 2024 Oct; 230(4):889-900. PubMed ID: 38838218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.
    Yang Y; Yang M; Peng Y; Liang Y; Wei J; Xing L; Guo L; Li X; Li J; Wang J; Li M; Xu Z; Zhang M; Wang F; Shi Y; Yuan J; Liu Y
    Nat Microbiol; 2022 Mar; 7(3):423-433. PubMed ID: 35132197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients.
    Muecksch F; Wise H; Batchelor B; Squires M; Semple E; Richardson C; McGuire J; Clearly S; Furrie E; Greig N; Hay G; Templeton K; Lorenzi JCC; Hatziioannou T; Jenks S; Bieniasz PD
    J Infect Dis; 2021 Feb; 223(3):389-398. PubMed ID: 33140086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.
    Pradenas E; Trinité B; Urrea V; Marfil S; Tarrés-Freixas F; Ortiz R; Rovirosa C; Rodon J; Vergara-Alert J; Segalés J; Guallar V; Valencia A; Izquierdo-Useros N; Noguera-Julian M; Carrillo J; Paredes R; Mateu L; Chamorro A; Toledo R; Massanella M; Clotet B; Blanco J
    Cell Rep Med; 2022 Feb; 3(2):100523. PubMed ID: 35233547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.